Eva Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 19-06-2024
- Paid Up Capital ₹ 0.10 M
as on 19-06-2024
- Company Age 17 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.49 M
as on 19-06-2024
- Revenue 35.40%
(FY 2021)
- Profit 8.81%
(FY 2021)
- Ebitda 1237.71%
(FY 2021)
- Net Worth 21.71%
(FY 2021)
- Total Assets -13.60%
(FY 2021)
About Eva Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹4.49 M.
Preeti Pulasaria, Punit Pulasaria, and Pankaj Pulasaria serve as directors at the Company.
- CIN/LLPIN
U51102RJ2007PTC025239
- Company No.
025239
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Oct 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Eva Biotech Private Limited offer?
Eva Biotech Private Limited offers a wide range of products and services, including Diclofenac, Diclofenac Sodium Injection, Antibiotic Tablets & Capsules, Azithromycin Tablets, Nutraceuticals & Dietary Supplements, Multivitamin Tablets & Capsules, Anti Cancer Medicines, Ondansetron, Pharmaceutical Syrup, Dry Syrups.
Who are the key members and board of directors at Eva Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Preeti Pulasaria  | Director | 26-Oct-2007 | Current |
| Punit Pulasaria | Director | 25-May-2011 | Current |
| Pankaj Pulasaria | Director | 26-Oct-2007 | Current |
Financial Performance of Eva Biotech.
Eva Biotech Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 35.4% increase. The company also saw a slight improvement in profitability, with a 8.81% increase in profit. The company's net worth Soared by an impressive increase of 21.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eva Biotech?
In 2020, Eva Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 03 Oct 2019 | ₹1.49 M | Open |
Others Creation Date: 27 May 2019 | ₹3.00 M | Open |
How Many Employees Work at Eva Biotech?
Unlock and access historical data on people associated with Eva Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eva Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eva Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
